Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Itraconazole in Basal Cell Carcinoma
NCT02735356Phase 1Completed
- Start
- May 2016
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of itraconazole in basal cell carcinoma (BCC). Primary endpoint: Percentage change of Gli at 4 weeks. Started May 2016; status: completed.
02
Drugs
itraconazole
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02735356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735356.